Dapagliflozin Propanediol Monohydrate

Tier B — Position early

Bristol Myers Squibb

Originator

2012

First approval

Expiry (public)

$8.4B ▲

Peak sales

Small molecule

Type

Targets：SGLT2

Brand：Edistride, Forxiga, Farxiga

Indications (approved)：Chronic renal impairment, Heart failure, Kidney disease, Type 1 diabetes, Type 2 diabetes

Regional status

Approved

2014-01-08

Approved

2012-11-11

China

Approved

2017-03-10

Japan

Approved

2014-03-24

Factories producing this API2

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

2 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates4 routes

Originator routes × 1Optimised (non-patent) × 3Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 5 · Total yield /

DAPA-006461432-24-6DAPA-007461432-25-7DAPA-00121739-92-4DAPA-002103-73-1DAPA-003461432-22-4DAPA-004461432-23-5DAPA-00532384-65-9API · Dapagliflozin Propanediol Monohydrate

Code	CAS No.	Intermediate
DAPA-006	461432-24-6	(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
DAPA-007	461432-25-7 Available	(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
DAPA-001	21739-92-4 Available	5-bromo-2-chlorobenzoic acid
DAPA-002	103-73-1 Available	ethoxybenzene
DAPA-003	461432-22-4 Available	(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
DAPA-004	461432-23-5 Available	4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
DAPA-005	32384-65-9 Available	(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one

OptimisedRoute 2Steps 5 · Total yield 14 g

DAPA-00121739-92-4DAPA-002103-73-1DAPA-003461432-22-4DAPA-004461432-23-5DAPA-00532384-65-9DAPA-006461432-24-6DAPA-008960404-62-0API · Dapagliflozin Propanediol Monohydrate

Code	CAS No.	Intermediate
DAPA-001	21739-92-4 Available	5-bromo-2-chlorobenzoic acid
DAPA-002	103-73-1 Available	ethoxybenzene
DAPA-003	461432-22-4 Available	(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
DAPA-004	461432-23-5 Available	4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
DAPA-005	32384-65-9 Available	(3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one
DAPA-006	461432-24-6	(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol
DAPA-008	960404-62-0	L-proline compound with (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1)

OptimisedRoute 3Steps 3 · Total yield 30 mg

DAPA-003461432-22-4DAPA-009498-07-7DAPA-0101432591-75-7DAPA-0111432591-86-0API · Dapagliflozin Propanediol Monohydrate

Code	CAS No.	Intermediate
DAPA-003	461432-22-4 Available	(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
DAPA-009	498-07-7	(1R,2S,3S,4R,5R)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
DAPA-010	1432591-75-7	(1R,2S,3S,4R,5R)-2,4-bis((tert-butyldiphenylsilyl)oxy)-6,8-dioxabicyclo[3.2.1]octan-3-ol
DAPA-011	1432591-86-0	(2S,3R,4S,5S,6R)-3,5-bis((tert-butyldiphenylsilyl)oxy)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methyltetrahydro-2H-pyran-4-ol

OptimisedRoute 4Steps 4 · Total yield /

DAPA-003461432-22-4DAPA-012492-62-6DAPA-0133282-30-2DAPA-0141213234-53-7DAPA-01581058-27-7DAPA-0161363332-73-3API · Dapagliflozin Propanediol Monohydrate

Code	CAS No.	Intermediate
DAPA-003	461432-22-4 Available	(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone
DAPA-012	492-62-6	(2S,3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol
DAPA-013	3282-30-2	pivaloyl chloride
DAPA-014	1213234-53-7	(2R,3R,4S,5R,6R)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetrakis(2,2-dimethylpropanoate)
DAPA-015	81058-27-7	(2R,3R,4S,5R,6R)-2-bromo-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)
DAPA-016	1363332-73-3	(2S,3S,4R,5R,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-((pivaloyloxy)methyl)tetrahydro-2H-pyran-3,4,5-triyl tris(2,2-dimethylpropanoate)

Frequently asked questions

What are the approved indications of Dapagliflozin Propanediol Monohydrate?

Approved indications include: Chronic renal impairment, Heart failure, Kidney disease, Type 1 diabetes, Type 2 diabetes.

When does the Dapagliflozin Propanediol Monohydrate patent expire?

No public expiry year is available for Dapagliflozin Propanediol Monohydrate yet; this page updates once verified.

How many synthesis routes are recorded for Dapagliflozin Propanediol Monohydrate?

4 synthesis routes are recorded; the shortest is 3 steps with 30 mg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Dapagliflozin Propanediol Monohydrate intermediates?

6 intermediate CAS of Dapagliflozin Propanediol Monohydrate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Dapagliflozin Propanediol Monohydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29